课题基金 / 基金详情

Moderate Hypertension in Pregnancy: Safety and Effectiveness of Treatment

Moderate Hypertension in Pregnancy: Safety and Effectiveness of Treatment
妊娠期中度高血压:治疗的安全性和有效性
批准号:
8960648
负责人:
SASCHA DUBLIN
金额:
$101.26万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-05 至 2019-06-30

项目摘要

项目成果

SASCHA DUBLIN的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(由申请人提供):背景和目标:在美国,高血压疾病每年影响30万名孕妇,增加了许多不良后果的风险,包括孕产妇和胎儿死亡。妊娠期重度高血压的治疗是常规的。然而,用药物治疗轻度到中度高血压是有争议的,因为对益处的多少存在不确定性,而且担心药物可能会损害胎儿。几乎没有严格的证据来帮助女性和她们的临床医生权衡治疗的风险和好处。随机试验的规模很小,限制了它们提供确凿答案的能力,特别是在不同药物的比较中。到目前为止,观察性研究缺乏关于实际血压水平的数据,无法解释不同治疗方式的女性高血压严重程度的差异。没有研究调查治疗的风险和益处是否因母亲的种族/民族或肥胖状况而不同。这项研究将通过使用妊娠合并轻度至中度高血压的真实临床数据来填补这些空白,以确定接受治疗和未接受治疗的妇女以及药物类别和妇女亚组之间的母婴结局有何不同。结果将提供重要的新证据,以支持更知情和更有效的治疗决定。方法:本项目是一项回顾性队列研究,设置在3个综合医疗保健提供系统(Kaiser Permanente North California、Kaiser Permanente Southern California和Group Health)中,这些系统维护全面的电子医疗记录(EMR),包括孕前和孕期血压值的广泛数据。33,000名患有轻中度慢性或妊娠期高血压的孕妇的健康计划数据,与各州的出生和胎儿死亡证明数据相关联,将被用于解决这些目标:1)评估与不治疗相比,药物治疗对重要母婴结局的影响,同时考虑两组之间高血压严重程度和其他因素的差异;2)比较不同降压药对临床重要结果的风险;3)确定不同母亲种族/族裔或肥胖状况的益处和风险是否有所不同。要研究的主要结果是先兆子痫、早产、胎龄偏小、先天性畸形、产妇或新生儿重症监护病房入院,以及胎儿或婴儿死亡。影响:这项研究将确定治疗轻度到中度妊娠期高血压的风险和好处。结果可能会立即影响临床实践,帮助女性和提供者一起做出更明智的选择。最终,循证治疗将通过帮助临床医生保护产妇健康,同时保护胎儿生长并促进在足月或近期分娩,来改善公共卫生。
英文摘要
 DESCRIPTION (provided by applicant): Background and goals: Hypertensive disorders affect 300,000 pregnancies in the US each year, increasing the risk of many adverse outcomes including maternal and fetal death. Treatment of severe hypertension in pregnancy is routine. Treatment of mild to moderate hypertension with medications is controversial, however, because of uncertainty about the amount of benefit and concern that medications may harm the fetus. Little rigorous evidence exists to help women and their clinicians weigh treatment risks and benefits. Randomized trials have been small in size, limiting their ability to provide conclusive answers, particularly for comparisons of different medications. Observational studies thus far have lacked data on actual blood pressure levels, preventing them from accounting for differences in hypertension severity between women treated in different ways. No studies have investigated whether risks and benefits of treatment differ by maternal race/ethnicity or obesity status. This study will fill these gaps by using real-world clinical data on pregnancies complicated by mild to moderate hypertension to determine how maternal and infant outcomes differ in treated and untreated women as well as between medication classes and subgroups of women. Results will provide important new evidence to support more informed and effective treatment decisions. Methods: This project is a retrospective cohort study set within 3 integrated health care delivery systems (Kaiser Permanente Northern California, Kaiser Permanente Southern California, and Group Health) that maintain comprehensive electronic medical records (EMRs), including extensive data on blood pressure values before and during pregnancy. Health plan data for 33,000 pregnant women with mild to moderate chronic or gestational hypertension delivering from 2007 through 2014, linked to state birth and fetal death certificate data, will be used to address these aims: 1) Evaluate the effect of pharmacologic treatment, compared to no treatment, on important adverse maternal and infant outcomes, while taking into account differences in hypertension severity and other factors between the groups; 2) Compare the risks of clinically important outcomes with different antihypertensive medications; 3) Determine whether the benefits and risks vary by maternal race/ethnicity or obesity status. The primary outcomes to be studied are preeclampsia, preterm birth, small size for gestational age, congenital malformations, maternal or neonatal intensive care unit admission, and fetal or infant death. Impact: This research will determine risks and benefits of treating mild to moderate hypertension in pregnancy. Results may immediately affect clinical practice, helping women and providers make more informed choices together. Ultimately, evidence-based treatment will improve public health by helping clinicians protect maternal health while preserving fetal growth and promoting delivery at or near term.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multidomain Alzheimers Risk Reduction Study (MARRS) Pilot
Moderate Hypertension in Pregnancy: Safety and Effectiveness of Treatment
Elective Induction of Labor and Pregnancy Outcomes
Elective Induction of Labor and Pregnancy Outcomes
海外基金